Meeting Minutes: Drug Formulary Committee - DRAFT

Date & Time: March 28, 2019; 5:30-9 PM
Minutes prepared by: Hind Douiki and Dave Hoang
Location: Elmer Andersen Building, Room 2370, 540 Cedar Street, St. Paul, MN  55101

Attendance

• Members absent: Kathryn Lombardo, M.D.; Kyle Lehenbauer, M.D.; Monica Brands, R.Ph
• DHS staff present: Jeff Schiff, M.D., MBA; Chad Hope, Pharm.D.; Dave Hoang, Pharm.D., MBA; Mary Beth Reinke, Pharm.D., MSA.; Sharon Feinstein-Rosenblum PharmD
• Others in attendance: Hind Douiki, Pharm.D.; Ariane Casey, Pharm.D.

Report of the Chair

Dr. Ness presided over the meeting.

Approval of Minutes

Minutes from the February 2019 meeting were reviewed; Dave Hoang amended to replace “currently posted PDL”, in the minutes document, to “PDL document dated January 11, 2019”. Minutes were approved as amended.

DHS Housekeeping

• Dave Hoang introduced a new DFC committee member: Ramona Powell, PharmD.
• Chad Hope reminded the DFC committee members that the annual ethics training is postponed. DFC members are asked to complete submit a conflict of interest disclosure form once a year.

Old Business

• None

New Business

New Specialty Drugs for Continued PA
• The committee discussed Epidiolex and recommended to the department by a unanimous vote that Epidiolex remain on PA.

Preferred Drug List

• DHS FFS PDL is posted at: https://mn.gov/dhs/assets/preferred-drug-list-fee-for-service_tcm1053-292127.pdf
• Dave indicated that at this meeting the committee will review the drug classes that have proposed changes since the last DFC meeting.
• The committee discussed the Acne Agents, Topical therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Acne Agents, Topical drugs remain as they are presented on the PDL document dated March 28, 2019.
• The committee discussed the Alzheimer’s Agents therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Alzheimer’s Agents drugs remain as they are presented on the PDL document dated March 28, 2019.
• The committee discussed the Angiotensin Modulator Combinations therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Angiotensin Modulator Combinations drugs remain as they are presented on the PDL document dated March 28, 2019.
• The committee discussed the Antibiotics, GI therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Antibiotics, GI drugs remain as they are presented on the PDL document dated March 28, 2019.
• The committee discussed the Antibiotics, Inhaled therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Antibiotics, Inhaled drugs remain as they are presented on the PDL document dated March 28, 2019.
• The committee discussed the Anticoagulants therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Anticoagulants drugs remain as they are presented on the PDL document dated March 28, 2019.
• The committee discussed the Antidepressants, SSRIs therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Antidepressants, SSRIs drugs remain as they are presented on the PDL document dated March 28, 2019.
• The committee discussed the Antifungals, Oral therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Antifungals, Oral drugs remain as they are presented on the PDL document dated March 28, 2019, with the removal of Voriconazole Tablet from the PDL and to present it to the DFC committee for review for drug-specific PA criteria.
• The committee discussed the Antihistamines, Minimally Sedating therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Antihistamines, Minimally Sedating drugs remain as they are presented on the PDL document dated March 28, 2019.
• The committee discussed the Antiparasitics, Topical therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Antiparasitics, Topical drugs remain as they are presented on the PDL document dated March 28, 2019.
• The committee discussed the Beta Blockers therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Beta Blockers drugs remain as they are presented on the PDL document dated March 28, 2019.
• The committee discussed the Bladder Relaxant Preparations therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Bladder Relaxant Preparations drugs remain as they are presented on the PDL document dated March 28, 2019.
• The committee discussed the Bone Resorption Suppression And Related Agents therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Bone Resorption Suppression And Related Agents drugs remain as they are presented on the PDL document dated March 28, 2019, with the removal of Prolia from the PDL as it is office-administered.
• The committee discussed the BPH Treatments therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred BPH Treatments drugs remain as they are presented on the PDL document dated March 28, 2019.
• The committee discussed the Bronchodilators, Beta Agonist therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Bronchodilators, Beta Agonist drugs remain as they are presented on the PDL document dated March 28, 2019.
• The committee discussed the Cephalosporins And Related Antibiotics therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Cephalosporins And Related Antibiotics drugs remain as they are presented on the PDL document dated March 28, 2019.
• The committee discussed the COPD Agents therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred COPD Agents drugs remain as they are presented on the PDL document dated March 28, 2019.
• The committee discussed the Fluoroquinolones, Oral therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Fluoroquinolones, Oral drugs remain as they are presented on the PDL document dated March 28, 2019.
• The committee discussed the Glucocorticoids, Inhaled therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Glucocorticoids, Inhaled drugs remain as they are presented on the PDL document dated March 28, 2019.
• The committee discussed the Hypoglycemics, Alpha-Glucosidase Inhibitors therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Hypoglycemics, Alpha-Glucosidase Inhibitors drugs remain as they are presented on the PDL document dated March 28, 2019.
• The committee discussed the Hypoglycemics, Insulin And Related Agents therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Hypoglycemics, Insulin And Related Agents drugs remain as they are presented on the PDL document dated March 28, 2019.
• The committee discussed the Hypoglycemics, TZD therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Hypoglycemics, TZD drugs remain as they are presented on the PDL document dated March 28, 2019.
• The committee discussed the Intranasal Rhinitis Agents therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Intranasal Rhinitis Agents drugs remain as they are presented on the PDL document dated March 28, 2019.
• The committee discussed the Leukotriene Modifiers therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Leukotriene Modifiers drugs remain as they are presented on the PDL document dated March 28, 2019.
• The committee discussed the Lipotropics, Other therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Lipotropics, Other drugs remain as they are presented on the PDL document dated March 28, 2019.
The committee discussed the Lipotropics, Statins therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Lipotropics, Statins drugs remain as they are presented on the PDL document dated March 28, 2019.

The committee discussed the Macrolides/Ketolides therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Macrolides/Ketolides drugs remain as they are presented on the PDL document dated March 28, 2019.

The committee discussed the Multiple Sclerosis Agents therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Multiple Sclerosis Agents drugs remain as they are presented on the PDL document dated March 28, 2019, with the removal of Zinbryta from the PDL as it was pulled out from the market on 3/3/19, as well as the removal of Tysabri, Ocrevus, and Lemtrada from the PDL as they are IV-administered.

The committee discussed the Ophthalmic Antibiotics therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Ophthalmic Antibiotics drugs remain as they are presented on the PDL document dated March 28, 2019.

The committee discussed the Ophthalmics For Allergic Conjunctivitis therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Ophthalmics For Allergic Conjunctivitis drugs remain as they are presented on the PDL document dated March 28, 2019.

The committee discussed the Ophthalmics, Glaucoma Agents therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Ophthalmics, Glaucoma Agents drugs remain as they are presented on the PDL document dated March 28, 2019.

The committee discussed the Opiate Dependence Treatments therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Opiate Dependence Treatments drugs remain as they are presented on the PDL document dated March 28, 2019.

The committee discussed the Otic Antibiotics therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Otic Antibiotics drugs remain as they are presented on the PDL document dated March 28, 2019.

The committee discussed the PAH Agents, Oral And Inhaled therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred PAH Agents, Oral And Inhaled drugs remain as they are presented on the PDL document dated March 28, 2019.

The committee discussed the Phosphate Binders therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Phosphate Binders drugs remain as they are presented on the PDL document dated March 28, 2019.

The committee discussed the Progestins for Cachexia therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Progestins for Cachexia drugs remain as they are presented on the PDL document dated March 28, 2019.

The committee discussed the Sedative Hypnotics therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Sedative Hypnotics drugs remain as they are presented on the PDL document dated March 28, 2019.

The committee discussed the Smoking Cessation therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Smoking Cessation drugs remain as they are presented on the PDL document dated March 28, 2019.

The committee discussed the Ulcerative Colitis Agents therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Ulcerative Colitis Agents drugs remain as they are presented on the PDL document dated March 28, 2019.
• Al Heaton made a motion to remove all IV-administered Antiemetic/Antivertigo Agents drugs from the PDL. Motion was accepted.
• Kelly Ruby made a motion to add a long-acting incretin mimetic. Motion was accepted; Bydureon Pen (Subcutane.) was changed from non-preferred to preferred on the PDL.
• The committee discussed Xarelto 2.5 mg, Eliquis, and Savaysa and recommended to the department by a unanimous vote that Xarelto 2.5 mg, Eliquis, and Savaysa remain on PA.
• The committee discussed the entire PDL and recommended to the department by a unanimous vote that the entire PDL is approved as discussed in this meeting.

Adjournment

• The meeting was adjourned at approximately 8:35 PM Central Time.